Adjuvant Trastuzumab Therapy: Can We Balance Efficacy and Safety? Journal Articles

abstract

• Abstract Trastuzumab is an effective treatment for HER2-positive breast cancer. Current guidelines recommend withholding trastuzumab in patients experiencing a significant asymptomatic decline in left ventricular function. In this commentary, we discuss the survival benefits afforded by trastuzumab juxtaposed against the risk of trastuzumab-mediated cardiotoxicity. It is not known whether the net benefit of continuing trastuzumab in the setting of mild cardiotoxicity outweighs the associated risks. We describe a potential approach undertaken by our group, and others, and call for a randomized trial.

authors

• Kumar Tyagi, Nidhi
• Barron, Carly C
• Tyagi, Nidhi Kumar
• Alhussein, Muhammad Mustafa
• Mukherjee, Som
• Ellis, Peter
• Dhesy-Thind, Sukhbinder
• Leong, Darryl

status

• published 

publication date

• November 1, 2019

has subject area

• 1112 Oncology and Carcinogenesis (FoR)
• Antineoplastic Agents, Immunological (MeSH)
• Breast Neoplasms (MeSH)
• Cardiotoxicity (MeSH)
• Chemotherapy, Adjuvant (MeSH)
• Dose-Response Relationship, Drug (MeSH)
• Female (MeSH)
• Heart Failure (MeSH)
• Humans (MeSH)
• Oncology & Carcinogenesis (Science Metrix)
• Patient Safety (MeSH)
• Prognosis (MeSH)
• Trastuzumab (MeSH)

published in

• Oncologist  Journal

keywords

• Antineoplastic Agents, Immunological
• Breast Neoplasms
• Breast cancer
• Cardiotoxicity
• Cardio‐oncology
• Chemotherapy, Adjuvant
• Dose-Response Relationship, Drug
• Female
• HER2
• Heart Failure
• Humans
• Patient Safety
• Prognosis
• Trastuzumab

Digital Object Identifier (DOI)

• 10.1634/theoncologist.2019-0263

start page

• 1405

end page

• 1409

volume

• 24

issue

• 11